Children’s Health Defense demanded that the Food and Drug Administration (FDA) withdraw its approval of the antiviral drug remdesivir for children.
Dr. Madhava Setty, senior science editor for CHD’s Defender newsletter, cited 72 percent of children hospitalized with COVID-19 who “suffered adverse events” as a reason why remdesivir should not be approved.
Children’s Health Defense demands FDA withdraw its approval of Remdesivir for infants and children, citing 72% adverse events rate https://t.co/ukD524ruHU
— ꧁✬Ｈυ𝓵ᵃ𝔥卂ᶰ𝓭ѕ✬꧂ (@ThehulaG) May 4, 2022
The Defender noted from the clinical study results:
According to the press release, the FDA’s decision to approve the therapy, marketed under the name Veklury, is supported by a clinical study conducted on infants 4 weeks and older weighing a minimum of 6.6 pounds.
The study is underway and will not be completed until February 2023. There are no published results.
However, Gilead Sciences, maker of remdesivir and sponsor of the study, provided the following details in a company press release:
- A total of 53 hospitalized pediatric patients were enrolled in the clinical study.
- 72% suffered adverse events.
- 21% suffered serious adverse events determined to be unrelated to the drug.
- Three children died from either underlying conditions or COVID-19.
Nevertheless, Gilead Science assured that “no new safety signals were apparent for patients treated with Veklury.”
The study was of single-arm, open-label design.
A single-arm study has no control group, making it impossible to compare its effectiveness against standard of care.
Open-label means participants and investigators were aware they were receiving the drug, making it impossible to separate placebo from drug effect.
Despite zero evidence showing any benefit of the antiviral drug for children, the FDA approved its use in pediatric patients 28 days of age and older.
In fact, studies in adults show remdesivir has zero benefits for all age groups.
Even the World Health Organization recommended against remdesivir to treat COVID-19 in November 2020.
The global health agency changed its guidance on April 22, 2022 to use remdesivir in mild or moderate COVID-19 patients who are at high risk of hospitalization (surely no corruption behind the change of guidance).
In an April 26 report, the Centers for Disease Control and Prevention (CDC) estimated that three out of every four children in the U.S. have already had COVID. “It’s shocking that our federal health agencies are completely ignoring the fact that so many children have developed natural immunity to COVID,” said Children’s Health Defense (CHD) chief science director Dr. Brian Hooker. “When they do have COVID, young children are at virtually zero risk for serious complications or death. The FDA should rescind its approval of such a dangerous drug for this age group.”
In fact, the withdrawal of remdesivir should include everyone.
Review previous studies and reports of this toxic drug below: